# Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

> **NCT01685125** · PHASE2 · UNKNOWN · sponsor: **University of Southern California** · enrollment: 96 (estimated)

## Conditions studied

- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** abiraterone acetate
- **DRUG:** dasatinib
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT01685125
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-09
- **Primary completion:** 2016-03
- **Final completion:** 2018-03
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2017-07-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01685125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01685125, "Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01685125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*